aBLA Filing Intelligence & Biosimilar Opportunity

Unloxcyt

Cosibelimab-Ipdl

Anticancer

Injection

Unloxcyt is an IV anti–PD-L1 antibody for adults with advanced or metastatic cutaneous squamous cell carcinoma who are not surgical or radiation candidates. It helps the immune system fight cancer by blocking PD-L1, with a documented response in nearly half of patients.

Approval Date

13-Dec-24

Data Exclusivity Expiry

13-Dec-28

Market Exclusivity Expiry

13-Dec-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

117

2028

171

2029

242

2030

310

2031

385

2032

464

Molecule profile

Details & specifications

Molecule

Cosibelimab-Ipdl

Innovator

CHECKPOINT THERAPEUTICS INC

Dosage Form

Injection

Strength

300 mg/5 mL (60 mg/mL)

Therapeutic Category

Anticancer

Usage

To treat cutaneous squamous cell carcinoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.